NICOLA LAWRENCE: Open Payments
NPI 1073531109 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,096 in 160 payments from 15 companies in 2025. Trend: 2023 $1,981 · 2024 $3,180 · 2025 $3,096
Food & beverage: $3,096
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $551 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $382 |
| Otsuka America Pharmaceutical, Inc. | 10 | $357 |
| Vanda Pharmaceuticals Inc. | 9 | $286 |
| Alkermes, Inc. | 11 | $222 |
| ABBVIE INC. | 18 | $215 |
| Teva Pharmaceuticals USA, Inc. | 12 | $214 |
| Janssen Pharmaceuticals, Inc | 6 | $209 |
| Almatica Pharma LLC | 14 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $154 |
Products named: INGREZZA, CAPLYTA, REXULTI, FANAPT, ARISTADA, VRAYLAR, AUSTEDO XR, LOREEV XR.
Industry payments across AZ — which companies pay providers there.
